SecBot SecBot
EFFECT ·Filed May 15, 2026

KPTI

Karyopharm Therapeutics Inc.
BEARISH
Impact 7/10
Horizonimmediate Processed6mo ago SEC9999999995-26-001656
Actionable Insight ▼ Bearish

Expect near-term downward pressure as the market absorbs the massive overhang. Watch for any immediate ATM sales or registered secondary offerings; further weakness likely until Karyopharm clarifies its financing plan or shows a path to profitability.

DirectionBearish
Confidencehigh
Horizonimmediate

How the stock moved after the report

⚠ Clustered BEARISH VIEWSTOCK ABOVE ENTRY AT T+20
Entry
$7.67
T+0 close · May 15, 2026 · via day close
Latest settled
+25.68%
T+20 · $9.64
Vs SPY
+23.57%
α at T+20
Next horizon
T+60
due 3mo ago
  1. T+0 · May 15 $7.67entry
  2. T+1 · 6mo ago −6.91%α −6.85% · $7.14
  3. T+5 · 6mo ago +6.39%α +5.43% · $8.16
  4. T+20 · 5mo ago +25.68%α +23.57% · $9.64
  5. T+60 · due 3mo ago Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Two shelf registrations effective: a $400M universal shelf (including $100M ATM) and an 8.8M-share resale shelf. This enables immediate equity dilution at a company with a $201M market cap and going-concern doubts, dramatically increasing supply risk.

Key Facts

  • Both S-3 shelves (Nos. 333-295533 and 333-295535) declared effective May 14, 2026.
  • $400M universal shelf includes $100M ATM; potential dilution ~200% of current market cap.
  • 8.8M-share resale shelf for RA Capital (no proceeds to company) also effective.
  • Auditor has expressed substantial doubt about Karyopharm's ability to continue as a going concern.
  • No financial proceeds from the resale shelf; proceeds from universal shelf would be used for general corporate purposes.

Financial Impact

Potential dilution exceeding 200% of $201M market cap via the $400M universal shelf; additional 8.8M shares from resale shelf (about 4.4% of current float).

dilutionmarket capstock price

Risk Factors

  • Immediate dilutive share sales under the ATM or universal shelf.
  • Continued going concern uncertainty limiting institutional demand.
  • Failure to secure non-dilutive financing alternatives.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
85% bullish (13 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
EFFECT Filing (KPTI), Batch item 19999999995-26-001656
Document: 9999999995-26-001656-index.html9999999995-26-001655
Document: 9999999995-26-001656.txt9999999995-26-001656
EFFECT Filing (KPTI), Batch item 49999999995-26-001655
Document: 9999999995-26-001655-index.html9999999995-26-001656
Document: 9999999995-26-001655.txt9999999995-26-001656

US Market Status

Market Closed · Opens Wed (10h 8m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 15, 2026